Skip to main content
. 2016 Oct 26;2(1):23–30. doi: 10.1177/2396987316677197

Table 2.

Patients profile according to early neurological deterioration.

END group (n = 86, 11.2%) Non-END group (n = 685, 88.8%) P-value
Age (mean ± SD), years 74.8 ± 7.9 71.9 ± 7.0 <0.001
Male, n (%) 55 (64.0) 400 (58.4) 0.323
BMI (mean ± SD), kg/m2 23.0 ± 3.9 23.1 ± 3.0 0.840
Hypertension, n (%) 41 (47.7) 296 (43.2) 0.432
Diabetes mellitus, n (%) 14 (16.3) 138 (20.1) 0.396
Hyperlipidaemia, n (%) 14 (16.3) 108 (15.8) 0.902
Smoking, n (%) 3 (7.3) 38 (5.5) 0.610
Previous stroke/TIA, n (%) 11 (12.8) 65 (9.5) 0.333
Coronary heart disease, n (%) 6 (7.0) 15 (2.2) 0.022
Atrial fibrillation, n (%) 10 (13.7) 63 (9.2) 0.468
Initial NIHSS (median (IQR)) 4 (0–9.25) 3 (1–6) 0.844
Stroke mechanism, n (%) 0.222
 LAA 26 (30.2) 222 (32.4)
 SVO 13 (15.1) 162 (23.6)
 CE 29 (33.7) 166 (24.2)
 Other determined 6 (7.0) 36 (5.3)
 Undetermined 12 (14.0) 99 (14.5)
Lesion location, n (%) 0.005
 Anterior circulation 50 (58.1) 409 (59.7)
 Posterior circulation 17 (19.9) 202 (29.5)
 Multiple territory 19 (22.1) 74 (10.8)
Significant stenosis on relevant artery, n (%) 40 (46.5) 264 (38.5) 0.154
Infection, n (%) 12 (14.0) 45 (6.6) 0.014
Initial BT (℃) 36.46 ± 0.39 36.39 ± 0.40 0.156
eGFR (mean ± SD), mL/min/1.73 m2 89.1 ± 23.6 86.3 ± 19.4 0.220
Quartiles of Cystatin C 0.002
 Q1 (0.080–0.734) 13 (15.1) 179 (26.1)
 Q2 (0.737–0.821) 17 (19.8) 176 (25.7)
 Q3 (0.822–0.935) 26 (30.2) 167 (24.4)
 Q4 (0.936–2.060) 30 (34.9) 163 (23.8)
Laboratory information (mean ± SD)
 White blood cell count (×103/µL) 8.13 ± 2.56 7.51 ± 2.47 0.029
 Fasting blood sugar (mg/dL) 116.88 ± 38.71 107.49 ± 34.48 0.019
 Cystatin C (mg/L) 0.892 ± 0.190 0.838 ± 0.176 0.009
 C-reactive protein (mg/dL) 1.03 ± 2.05 0.60 ± 1.51 0.064

END: early neurological deterioration; BMI: body mass index; TIA: transient ischaemic stack; LAA: large artery atherosclerosis; SVO: small-vessel occlusion; CE: cardioembolism; BT: body temperature; eGFR: estimated glomerular filtration rate.